Commercial Opportunities from Biomarkers: Transforming Drug Discovery, Clinical Development and Molecular Diagnostics

Published by: Business Insights

Published: May. 1, 2006 - 206 Pages

Table of Contents

Executive Summary

Biomarkers in drug discovery, development and clinical diagnostics

Regulatory acceptance of biomarkers now and in the future

Fishing for new drug targets with biomarkers

Biomarkers aiding go/no go decisions

Imaging biomarkers directing clinical dosing studies

Clinical biomarkers improving trial design

Biomarkers as surrogate endpoints

Market size, collaborations and future directions

Chapter 1 Biomarkers in drug discovery, development and clinical diagnostics

Summary

Introduction

The role of biomarkers in drug discovery, preclinical, clinical development and diagnostics

Biomarkers in the drug discovery process

Safety/toxicology biomarkers

Efficacy or outcome biomarkers and surrogate endpoints

Biomarkers: challenges and opportunities

Chapter 2 Regulatory acceptance of biomarkers now and in the future

Summary

Introduction

The critical path initiative and FDA guidance

Regulatory guidance from the other major markets

Europe - the European Medicines Agency (EMEA)

Japan - the Ministry of Health and Welfare (MHLW)

Regulatory agencies working together

Other biomarker initiatives

Regulatory acceptance of a valid biomarker

Regulatory acceptance of in vitro diagnostic biomarkers

Costs and incentives for biomarker development and validation

Conclusions

Chapter 3 Fishing for new drug targets with biomarkers

Summary

Introduction

Target discovery via functional genomics

What is functional genomics?

Target discovery

New technologies in functional genomics

DNA and protein microarrays

New technologies

The genomics-derived drug pipeline

Case study - target discovery by CuraGen Corporation

The future of genomics technologies for drug target identification

Biomarker discovery via proteomics

What is proteomics?

Proteomics in biomarker development: the HUPO Project

Case studies - Biomarker development using proteomic technologies

Caprion Pharmaceuticals Inc. case study

Millennium Pharmaceuticals case study

Limitations of proteomics for biomarker discovery

Integrating ‘omics in biomarker discovery: metabonomics

What is metabonomics?

Metabonomics-based biomarker discovery - case studies

Metabolon Inc case study

Phenomenone Discoveries case study

Limitations of metabonomics

Conclusions

Chapter 4 Biomarkers aiding go/no go decisions

Summary

Introduction

Technologies for safety biomarker discovery

Toxicogenomics

Genomic biomarkers for drug-induced nephrotoxicity, genotoxicity and neutropenia

Proteomic biomarkers of drug-induced hepatotoxicity and cardiotoxicity

Metabonomic biomarkers for vasculitis and hepatotoxicity

Databases for predictive toxicogenomics

Privately held databases

Publicly held databases

Challenges and opportunities

Challenges

Opportunities

Collaboration in biomarker discovery

Conclusions

Chapter 5 Imaging biomarkers directing clinical dosing studies

Summary

Introduction

Imaging biomarkers

X-ray and computed tomography

Magnetic resonance imaging

Novel MRI imaging agents

Positron emission tomography

Molecular imaging

The role of imaging biomarkers in preclinical studies

Bioluminescence

Matrix metalloproteinase inhibition

The role of imaging biomarkers in clinical studies

Phase 1: the role of imaging biomarkers in pharmacokinetic and dosing studies

Receptor occupancy studies

PET and MRI dosing strategies for anticancer agents

Phase 2 and 3: imaging biomarkers as study endpoints

Oncology

Multiple sclerosis

Rheumatoid arthritis

Alzheimer’s disease

Go/no-go decision making

Case study - VirtualScopics

Regulatory aspects of imaging technologies

Development of molecular imaging agents

Imaging biomarkers and surrogate endpoints

Conclusions

Chapter 6 Clinical biomarkers improving trial design

Summary

Introduction

Patient enrichment in clinical trials

Patient enrichment - advantages

Patient enrichment - potential problems

Targeted cancer treatments - case studies

Herceptin case study

Gleevec case study

Iressa case study

Patient enrichment via pharmacogenomics in therapeutic areas other than cancer

Vilazodone - case study

Pharmacogenomic testing in the pharmaceutical industry - an update

Conclusions

Chapter 7 Biomarkers as surrogate endpoints

Summary

Introduction

What is a surrogate endpoint?

Benefits and drawbacks of surrogate endpoints

Benefits

Drawbacks

Surrogate endpoint validation

Effective use of surrogates and examples

Case study - FDG-PET as a surrogate endpoint in oncology studies

CA-125 as a surrogate endpoint in trials of ovarian cancer

Costs of surrogate endpoint development

Regulatory perspective on surrogate endpoints

Conclusions

Chapter 8 Market size, collaborations and future directions

Summary

Introduction

The biomarker market

Potential cost savings in drug discovery and development

Market size

Genomics and proteomics

Metabonomics

Bioinformatics

Imaging

Molecular diagnostics

Companies and their alliances in the biomarker field

Outline of key companies

Key alliances

Alliances with pharmaceutical companies

Biomarker-diagnostic company alliances

Alliances with academia

Pharma strategies for biomarkers

Current and future trends for the evaluation of disease biomarkers

Conclusions

Chapter 9 Appendix

Biomarker discovery collaborations

Bibliography

Glossary

Index

Footnotes

List of Figures

Figure 1.1: Types of biomarker and examples

Figure 1.2: Low success rate of developmental drugs

Figure 1.3: The many roles of biomarkers in drug development

Figure 2.4: Voluntary genomic data submissions: process and outcomes

Figure 2.5: The EMEA and FDA working together

Figure 2.6: Valid DNA based biomarkers of enzyme activity

Figure 2.7: Exploratory DNA based biomarkers of enzyme or transporter activity

Figure 2.8: Fit-for-purpose qualification of biomarkers

Figure 2.9: Proposed biomarker validation in preclinical drug safety assessment

Figure 3.10: Genomics, proteomics and metabonomics: what is measured?

Figure 3.11: Technologies and methods used in biomarker discovery

Figure 3.12: A timeline for the introduction of various genomics technologies

Figure 3.13: The branches of proteomics for biomarker discovery

Figure 3.14: Scientific initiatives in the Human Proteome Organisation

Figure 3.15: CellCarta®: uses for proteomic analysis

Figure 3.16: An NMR metabonomic profile of urine

Figure 3.17: Metabonomic analysis of data from patients with ALS and controls

Figure 3.18: Biomarker discovery through metabolomics

Figure 4.19: Toxicogenomics and traditional toxicology working together to provide a framework for systems toxicology

Figure 4.20: Principal component analysis of gene expression changes following treatment with cisplatin, gentamicin and puromycin

Figure 4.21: Principal component analysis of urine from rats treated with a vasculitis causing compound

Figure 4.22: Database enabled predictive toxicology

Figure 4.23: Example of rank ordering candidate leads using the ToxExpress® Program

Figure 5.24: Imaging techniques and their uses

Figure 5.25: Targeted MRI imaging agents from Kereos Inc.

Figure 5.26: A PET/CT image indicating the uptake of 18F-fluoro-2-deoxy-D-glucose in a primary cancer lesion and a lymph node (orange areas)

Figure 5.27: Whole body microPET images through a rat showing 18F-FDG distribution

Figure 5.28: The VivoVision technology from Xenogen Inc.

Figure 5.29: NIRF data from rats treated with prinomastat

Figure 5.30: PET images of the serotonin 5-HT1A¬ receptors in the brain of a healthy volunteer before and after administration of pindolol

Figure 5.31: An MRI from a multiple sclerosis patient showing a T2 lesion

Figure 5.32: VirtualScopics’ method for tumor growth measurement

Figure 6.33: Targeted study designs

Figure 6.34: Imatinib mechanism of action in chronic myeloid leukaemia

Figure 6.35: Mechanism of action of gefinitib

Figure 6.36: Frequency of mutations by exon (EGFR tyrosine kinase domain)

Figure 6.37: The association between patients’ alleles for the serotonin transporter long/short polymorphism and response to SSRIs

Figure 7.38: Examples of biomarkers that have failed to serve as surrogate endpoints in clinical trials

Figure 7.39: Reasons for surrogate endpoint ‘failure’

Figure 7.40: Use of surrogate endpoints in antiretroviral approvals

Figure 8.41: Potential cost savings from the use of genomic biomarkers in drug discovery and development

Figure 8.42: Alliances between major pharmaceutical and biomarker discovery companies

Figure 8.43: Therapeutic areas represented by the major alliances of biomarker and pharmaceutical companies

Figure 8.44: Therapeutic areas represented by biomarker patents

Figure 8.45: Cancers represented by biomarker patents

Figure 8.46: Estimated time to the widespread use of biomarkers in different therapeutic areas

List of Tables

Table 3.1: Investments by pharmaceutical companies in genomics companies

Table 3.2: Highlights of drug discovery and development based on genomics technologies

Table 3.3: Companies predominantly using genomic and proteomic technologies for drug development

Table 4.4: Types of toxicogenomic biomarker

Table 4.5: Drugs extensively metabolized by CYP2C19 and CYP2D6

Table 5.6: Glucose-based imaging biomarkers for a variety of diseases

Table 5.7: Advantages of molecular imaging of whole animals for preclinical studies

Table 6.8: Comparison of targeted and untargeted study designs

Table 6.9: List of targeted cancer treatments

Table 6.10: Phase 3 trial outcome for Herceptin with and without HER2 diagnosis

Table 6.11: Examples of pharmacogenomic developments in therapeutic areas other than cancer

Table 6.12: Approval success rates for different therapeutic drug classes

Table 6.13: Currently marketed drugs that might benefit from pharmacogenomics

Table 7.14: Examples of surrogate endpoints and related clinical outcomes

Table 7.15: Sample size for Alzheimer’s disease clinical trials using volumetric MRI measures as a surrogate endpoint

Table 7.16: Uses of CA-125 in routine clinical care

Table 8.17: Biomarker market size and forecast ($bn), 2005-2012

Table 8.18: Molecular diagnostics market size and forecast ($bn), 2005-2012

Table 8.19: Genomics-based biomarker discovery companies

Table 8.20: Proteomics-based biomarker discovery companies

Table 8.21: Metabonomics-based biomarker discovery companies

Table 8.22: Bioinformatics companies in biomarker discovery

Table 8.23: Summary of major pharmaceutical company biomarker alliances

Table 8.24: Key diagnostic-biomarker company alliances

Table 8.25: Number of patents filed by various pharma and biomarker discovery companies

Table 9.26: Biomarker discovery collaborations with major pharma

Table 9.27: Biomarker discovery collaborations with major pharma (cont.)

Table 9.28: Biomarker discovery collaborations with major pharma (cont.)

Table 9.29: Biomarker discovery collaborations with smaller pharma or biotechnology companies

Table 9.30: Biomarker discovery collaborations with smaller pharma or biotechnology companies

(cont.)

Table 9.31: Biomarker discovery alliances with academia

Table 9.32: Biomarker discovery alliances with academia (cont.)

Abstract

• Analysis of leading pharmaceutical and biotechnology companies and academic groups at the forefront of biomarker discovery, validation and utilization.
• Examination of the key trends which are currently affecting the discovery and application of biomarkers such as the development of molecular diagnostics and the application of valid, probable valid and exploratory biomarkers in drug discovery.
• Assessment of the pivotal role that biomarkers play in the development of new diagnostic devices both in conjunction with drugs as targeted therapies and in areas of unmet medical need.

• The biomarker market is a relatively mature market and is forecast to quadruple to around $21.2bn by 2012 from just over $5.4bn in 2005, boosted primarily by growth in proteomics and metabonomics biomarker discovery.
• The application of pharmacogenomics to targeted studies, in which patient populations are enriched with potential responders, can lead to cost savings of around $80 million through the streamlining of clinical trials.
• The market for molecular diagnostics is gaining momentum, with Roche's AmpliChip P450 the first to receive regulatory approval. Tests for areas of high unmet need, such as Alzheimer's disease, are set to drive further growth in the market to 2012.
• The role of biomarkers spans all aspects of drug discovery and development from target discovery and validation, lead prioritization and optimization, study of drug and disease mechanisms, toxicity profiling and proof-of-concept in preclinical studies, to use in clinical trials as secondary and surrogate endpoints.

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.